Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

计划入组 28 人 · 首次发布于 2025 年 7 月 23 日

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 (CALIBRATE) (CALIBRATE)

计划入组 3 人

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

计划入组 13 人 · 首次发布于 2020 年 10 月 9 日

autosomal dominant polycystic kidney disease therapeutics

Autosomal dominant polycystic kidney disease(Maze Therapeutics)

autosomal dominant polycystic kidney disease therapy, Healx

NHI-1

United States

ALPHA-1 FOUNDATION, INC.

United States

Xi'an No.1 Hospital

China

BridgeBio Reports Positive Pipeline Progress and Q3 2024 Financial Results

BridgeBio's Attruby Sees Strong Early Demand; Phase 3 Trials Fully Enrolled

BridgeBio Plans Four Global Launches by 2027 as Attruby Annualizes Above $1 Billion